Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

about

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

Item

http://www.wikidata.org/entity/Q55008112

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@en

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@nl

type

Item

label

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@en

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@nl

prefLabel

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@en

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@nl

P1476

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

@en

P2093

Antonia De Socio

http://www.w3.org/2001/XMLSchema#string

Cristiana Barbati

http://www.w3.org/2001/XMLSchema#string

Fabio Massimo Perrotta

http://www.w3.org/2001/XMLSchema#string

Tania Colasanti

http://www.w3.org/2001/XMLSchema#string

P2860

Secukinumab for ankylosing spondylitis and psoriatic arthritis

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system.

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

P304

9101964

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/9101964

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29854850

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5954944

http://www.w3.org/2001/XMLSchema#string